Amgen's Repatha, or evolocumab, was approved by the European Commission to reduce low-density lipoprotein levels in adult patients with atherosclerotic cardiovascular disease to reduce cardiovascular risk. A FOURIER cardiovascular outcomes study showed that treatment with Repatha plus statins lessened the risk of heart attack by 27%, stroke by 21% and coronary revascularization procedures by 22% compared with statin therapy plus placebo over a 26-month treatment period.
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.